bluebird bio, Inc. (NASDAQ:BLUE) COO Susanna Gatti High sold 1,282 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $172.15, for a total transaction of $220,696.30. Following the sale, the chief operating officer now directly owns 13,718 shares in the company, valued at $2,361,553.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of bluebird bio, Inc. (BLUE) traded down $1.60 during midday trading on Friday, hitting $178.10. 504,089 shares of the stock were exchanged, compared to its average volume of 1,010,000. The firm has a market capitalization of $8,160.00, a PE ratio of -25.41 and a beta of 2.08. bluebird bio, Inc. has a 1-year low of $60.95 and a 1-year high of $222.03.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). The business had revenue of $7.71 million during the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. bluebird bio’s quarterly revenue was up 397.4% on a year-over-year basis. During the same quarter last year, the company earned ($2.07) earnings per share. sell-side analysts anticipate that bluebird bio, Inc. will post -6.72 earnings per share for the current year.
A number of brokerages recently issued reports on BLUE. Maxim Group reissued a “buy” rating and set a $170.00 price target (up from $100.00) on shares of bluebird bio in a report on Monday, October 9th. Wells Fargo & Co reissued an “outperform” rating and set a $158.00 price target (up from $134.00) on shares of bluebird bio in a report on Tuesday, September 5th. Morgan Stanley downgraded shares of bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 price objective on the stock. in a report on Monday, October 2nd. CIBC began coverage on shares of bluebird bio in a report on Thursday, December 21st. They set a “market perform” rating on the stock. Finally, Barclays began coverage on shares of bluebird bio in a report on Wednesday, September 6th. They set an “overweight” rating and a $151.00 price objective on the stock. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have issued a buy rating to the company’s stock. bluebird bio currently has a consensus rating of “Hold” and an average price target of $157.45.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.